GlaxoSmithKline

GlaxoSmithKline have yesterday announced their half year results, reporting robust gross margins and strong revenue growth across the portfolio, particularly in vaccines.

GSK has taken 195m orders for its swine flu vaccine and is currently in talks with over 50 countries over stockpiling the drug.